BACKGROUND AND OBJECTIVES: Guidelines for Stage II colon cancer recommend adjuvant chemotherapy (AC) only for tumors with high-risk features, but long-term outcomes data are mixed. We aimed to determine if AC was associated with a survival benefit in this population. METHODS: Patients were identified from the National Cancer Database and included if they met the following criteria: diagnosis of Stage II colon cancer, surgery, survival data, and complete data on six high-risk features. The cohort of 57 335 patients was stratified by receipt of AC. Subgroup analysis was performed on patients under the age of 65 years with no comorbidities. Overall survival (OS) was the primary endpoint. RESULTS: An increasing number of high-risk features was associated with significantly decreased median OS. AC was associated with significantly increased OS for patients with 0, 1, 2, and ≥3 high-risk features. On subgroup analysis, receipt of AC was associated with a reduced risk of death (hazard ratio: 0.66; confidence interval: 0.59-0.74). For patients in the subgroup who had a T4 tumor, AC was associated with increased OS (92.7 vs. 83.6 months). CONCLUSIONS: AC should be considered for all younger, healthy patients with Stage II colon cancer and may be associated with a survival benefit for patients with T4 disease.
BACKGROUND AND OBJECTIVES: Guidelines for Stage II colon cancer recommend adjuvant chemotherapy (AC) only for tumors with high-risk features, but long-term outcomes data are mixed. We aimed to determine if AC was associated with a survival benefit in this population. METHODS: Patients were identified from the National Cancer Database and included if they met the following criteria: diagnosis of Stage II colon cancer, surgery, survival data, and complete data on six high-risk features. The cohort of 57 335 patients was stratified by receipt of AC. Subgroup analysis was performed on patients under the age of 65 years with no comorbidities. Overall survival (OS) was the primary endpoint. RESULTS: An increasing number of high-risk features was associated with significantly decreased median OS. AC was associated with significantly increased OS for patients with 0, 1, 2, and ≥3 high-risk features. On subgroup analysis, receipt of AC was associated with a reduced risk of death (hazard ratio: 0.66; confidence interval: 0.59-0.74). For patients in the subgroup who had a T4 tumor, AC was associated with increased OS (92.7 vs. 83.6 months). CONCLUSIONS: AC should be considered for all younger, healthy patients with Stage II colon cancer and may be associated with a survival benefit for patients with T4 disease.
Authors: Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Mustafa A Arain; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Linda Farkas; Ignacio Garrido-Laguna; Jean L Grem; Andrew Gunn; J Randolph Hecht; Sarah Hoffe; Joleen Hubbard; Steven Hunt; Kimberly L Johung; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Eric D Miller; Mary F Mulcahy; Steven Nurkin; Michael J Overman; Aparna Parikh; Hitendra Patel; Katrina Pedersen; Leonard Saltz; Charles Schneider; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Kristina M Gregory; Lisa A Gurski Journal: J Natl Compr Canc Netw Date: 2021-03-02 Impact factor: 11.908
Authors: Paul F Engstrom; Juan Pablo Arnoletti; Al B Benson; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Anne Covey; Raza A Dilawari; Dayna S Early; Peter C Enzinger; Marwan G Fakih; James Fleshman; Charles Fuchs; Jean L Grem; Krystyna Kiel; James A Knol; Lucille A Leong; Edward Lin; Mary F Mulcahy; Sujata Rao; David P Ryan; Leonard Saltz; David Shibata; John M Skibber; Constantinos Sofocleous; James Thomas; Alan P Venook; Christopher Willett Journal: J Natl Compr Canc Netw Date: 2009-09 Impact factor: 11.908
Authors: Blake D Babcock; Mayada A Aljehani; Brice Jabo; Audrey H Choi; John W Morgan; Matthew J Selleck; Fabrizio Luca; Elizabeth Raskin; Mark E Reeves; Carlos A Garberoglio; Sharon S Lum; Maheswari Senthil Journal: Ann Surg Oncol Date: 2018-04-19 Impact factor: 5.344
Authors: J Philip Kuebler; H Samuel Wieand; Michael J O'Connell; Roy E Smith; Linda H Colangelo; Greg Yothers; Nicholas J Petrelli; Michael P Findlay; Thomas E Seay; James N Atkins; John L Zapas; J Wendall Goodwin; Louis Fehrenbacher; Ramesh K Ramanathan; Barbara A Conley; Patrick J Flynn; Gamini Soori; Lauren K Colman; Edward A Levine; Keith S Lanier; Norman Wolmark Journal: J Clin Oncol Date: 2007-04-30 Impact factor: 44.544
Authors: Genevieve M Boland; George J Chang; Alex B Haynes; Yi-Ju Chiang; Ryaz Chagpar; Yan Xing; Chung-Yuan Hu; Barry W Feig; Y Nancy You; Janice N Cormier Journal: Cancer Date: 2012-12-21 Impact factor: 6.860
Authors: Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg Journal: J Clin Oncol Date: 2004-04-05 Impact factor: 44.544